Literature DB >> 33490113

Advances in Pathogenesis of Idiopathic Membranous Nephropathy.

Zhifeng Xu1, Lu Chen2, Huiling Xiang1, Chun Zhang1, Jing Xiong1.   

Abstract

BACKGROUND: Membranous nephropathy (MN), a major cause of nephrotic syndrome, has attracted people's attention in recent years for its growing prevalence. It is the second or third leading cause of ESRD in patients with primary glomerulonephritis and is the leading glomerulopathy that recurs after kidney transplantation.
SUMMARY: MN can be classified as idiopathic membranous nephropathy (IMN) and secondary MN. The discovery of the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) provides the new diagnostic methods and treatment strategies for IMN on the molecular level. The study on single nucleotide polymorphism of IMN genes, such as the single M-type phospholipase A2 receptor 1 (PLA2R1) gene and human leukocyte antigen (HLA) gene, explains the pathogenesis of the disease from the perspective of genetics and conforms to the trend of the era of precision medicine. KEY MESSAGES: This review focuses on advances in the pathogenesis of IMN, including molecular and genetic pathogenesis, as well as discussing the diagnostic and treatment guiding value brought by these new discoveries.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Membranous nephropathy; Phospholipase A2 receptor; Podocyte autoantigen; Single nucleotide polymorphisms; Thrombospondin type-1 domain-containing 7A

Year:  2020        PMID: 33490113      PMCID: PMC7745661          DOI: 10.1159/000507704

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  82 in total

1.  Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis.

Authors:  Christos Bantis; Peter J Heering; Sendogan Aker; Magdalena Siekierka; Nicola Kuhr; Bernd Grabensee; Katrin Ivens
Journal:  Am J Nephrol       Date:  2006-01-02       Impact factor: 3.754

2.  The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype.

Authors:  B Rueda; J Broen; C Simeon; R Hesselstrand; B Diaz; H Suárez; N Ortego-Centeno; G Riemekasten; V Fonollosa; M C Vonk; F H J van den Hoogen; J Sanchez-Román; M A Aguirre-Zamorano; R García-Portales; A Pros; M T Camps; M A Gonzalez-Gay; M J H Coenen; P Airo; L Beretta; R Scorza; J van Laar; M F Gonzalez-Escribano; J L Nelson; T R D J Radstake; J Martin
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

3.  Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.

Authors:  A Radice; F Pieruzzi; B Trezzi; G Ghiggeri; P Napodano; M D'Amico; T Stellato; R Brugnano; F Ravera; D Rolla; G Pesce; M E Giovenzana; F Londrino; V Cantaluppi; F Pregnolato; A Volpi; G Rombolà; G Moroni; G Ortisi; Renato A Sinico
Journal:  J Nephrol       Date:  2017-10-28       Impact factor: 3.902

4.  Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Authors:  Taewoo Lee; Vimal K Derebail; Abhijit V Kshirsagar; Yunro Chung; Jason P Fine; Shannon Mahoney; Caroline J Poulton; Sophia Lionaki; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Michelle Hladunewich; Heather N Reich; Patrick H Nachman
Journal:  Kidney Int       Date:  2016-02-26       Impact factor: 10.612

5.  Association of STAT4 polymorphisms with susceptibility to primary membranous glomerulonephritis and renal failure.

Authors:  Shih-Yin Chen; Cheng-Hsu Chen; Yu-Chuen Huang; Chia-Jung Chan; Yao-Yuan Hsieh; Min-Chien Yu; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  Clin Chim Acta       Date:  2011-06-29       Impact factor: 3.786

6.  Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.

Authors:  Zhen Qu; Mu-Fan Zhang; Zhao Cui; Jia Wang; Miao Wang; Yi-Miao Zhang; Fang Wang; Xin Wang; Li-Qiang Meng; Xu-Yang Cheng; Gang Liu; Ming-Hui Zhao
Journal:  Am J Nephrol       Date:  2018-11-23       Impact factor: 3.754

7.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

Authors:  Laurence H Beck; Fernando C Fervenza; David M Beck; Ramon G B Bonegio; Fahim A Malik; Stephen B Erickson; Fernando G Cosio; Daniel C Cattran; David J Salant
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

8.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Elaine F Remmers; Robert M Plenge; Annette T Lee; Robert R Graham; Geoffrey Hom; Timothy W Behrens; Paul I W de Bakker; Julie M Le; Hye-Soon Lee; Franak Batliwalla; Wentian Li; Seth L Masters; Matthew G Booty; John P Carulli; Leonid Padyukov; Lars Alfredsson; Lars Klareskog; Wei V Chen; Christopher I Amos; Lindsey A Criswell; Michael F Seldin; Daniel L Kastner; Peter K Gregersen
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

9.  STAT4: a risk factor for type 1 diabetes?

Authors:  Maria I Zervou; Dimitrios Mamoulakis; Charalampos Panierakis; Dimitrios T Boumpas; George N Goulielmos
Journal:  Hum Immunol       Date:  2008-08-12       Impact factor: 2.850

10.  Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.

Authors:  Liyo Kao; Vinson Lam; Meryl Waldman; Richard J Glassock; Quansheng Zhu
Journal:  J Am Soc Nephrol       Date:  2014-09-09       Impact factor: 10.121

View more
  2 in total

1.  Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.

Authors:  Yan-Ni Wang; Hao-Yu Feng; Xin Nie; Ya-Mei Zhang; Liang Zou; Xia Li; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 2.  Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy.

Authors:  Hua Miao; Yamei Zhang; Xiaoyong Yu; Liang Zou; Yingyong Zhao
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.